Carlsmed Raises Full-Year Revenue Guidance Following 65% Growth
Carlsmed (CARL) has reported significant momentum with a 65% increase in revenue, prompting management to raise its full-year revenue guidance to a range of $78 million to $80 million. The company's growth is being driven by an expanding product portfolio and favorable shifts in Diagnosis Related Group (DRG) reimbursement landscapes. Looking ahead, the company expects continued expansion through upcoming Q4 product launches. CEO Michael Cordonnier highlighted that these developments are central to the company's strategy to broaden its market presence and capitalize on evolving healthcare payment models.
